NASDAQ:CUE Cue Biopharma (CUE) Stock Price, News & Analysis $18.21 -0.24 (-1.30%) As of 10:18 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Cue Biopharma Stock (NASDAQ:CUE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cue Biopharma alerts:Sign Up Key Stats Today's Range$17.74▼$18.8250-Day Range$16.08▼$37.8452-Week Range$4.97▼$45.50Volume2,371 shsAverage Volume342,822 shsMarket Capitalization$132.28 millionP/E RatioN/ADividend YieldN/APrice Target$83.00Consensus RatingHold Company Overview Cue Biopharma, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is designed to selectively activate a patient’s own T cells against disease-associated antigens while minimizing broad immune-system activation. Cue Biopharma’s product candidates are based on its Immuno-STAT (Selective Targeting and Alteration of T cells) platform, which uses biologic molecules intended to engage specific T-cell receptors and deliver immune-modulating signals. Its pipeline has included CUE-101, an investigational therapy targeting human papillomavirus type 16 (HPV16)-associated cancers, and CUE-102, which targets the Wilms’ tumor 1 (WT1) antigen expressed in several cancers. These programs have been evaluated in clinical studies, including research involving patients with recurrent or metastatic solid tumors. Founded in 2014 and headquartered in Boston, Massachusetts, Cue Biopharma conducts research and clinical development activities in the United States. The company’s programs remain investigational and are subject to clinical testing and regulatory review; they have not been established as safe or effective for commercial use.AI Generated. May Contain Errors. Read More Cue Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreCUE MarketRank™: 2.270196789225 of 5 starsCue Biopharma scored higher than 45% of companies evaluated by MarketBeat, and ranked 586th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingCue Biopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCue Biopharma has a consensus price target of $83.00, representing about 349.9% upside from its current price of $18.45.Amount of Analyst CoverageCue Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Cue Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cue Biopharma are expected to grow in the coming year, from ($21.79) to ($8.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cue Biopharma is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cue Biopharma is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cue Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.77% of the float of Cue Biopharma has been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 3.71, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cue Biopharma has recently increased by 12.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Cue Biopharma this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CUE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,430,815.00 in company stock.Percentage Held by Insiders14.56% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions35.04% of the stock of Cue Biopharma is held by institutions.Read more about Cue Biopharma's insider trading history. Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CUE Stock News HeadlinesCue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 1,144 Shares of Company StockOctober 15, 2026 | insidertrades.comCue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?September 26, 2026 | finance.yahoo.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.October 27 at 1:00 AM | Digest Publishing (Ad)Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOASeptember 21, 2026 | seekingalpha.comCue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug CandidateSeptember 21, 2026 | finance.yahoo.comCue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial ResultsSeptember 21, 2026 | finance.yahoo.comCue Biopharma Shares Jump With Positive Results in Chronic Spontaneous Urticaria TrialSeptember 21, 2026 | marketwatch.comCue Biopharma plummets on phase 2 data for chronic spontaneous urticaria assetSeptember 21, 2026 | msn.comSee More Headlines CUE Stock Analysis - Frequently Asked Questions How have CUE shares performed this year? Cue Biopharma's stock was trading at $274.86 at the beginning of 2026. Since then, CUE stock has decreased by 93.3% and is now trading at $18.45. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) issued its quarterly earnings data on Friday, August, 14th. The company reported ($24.14) earnings per share for the quarter, missing the consensus estimate of ($1.69) by $22.45. The company had revenue of $7.88 million for the quarter, compared to analysts' expectations of $3 million. Cue Biopharma had a negative net margin of 435.83% and a negative trailing twelve-month return on equity of 620.06%. When did Cue Biopharma's stock split? Cue Biopharma shares reverse split before market open on Thursday, April 23rd 2026.The 1-30 reverse split was announced on Wednesday, April 22nd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 22nd 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Cue Biopharma IPO? Cue Biopharma (CUE) raised $62 million in an initial public offering on Tuesday, January 2nd 2018. The company issued 8,820,710 shares at $6.00-$8.00 per share. Who are Cue Biopharma's major shareholders? Cue Biopharma's top institutional investors include Robertson Stephens Wealth Management LLC (0.15%). Insiders that own company stock include Shao-Lee Lin, Sumita Ray, Michael Vincent Meluzio and Daniel R Passeri. View institutional ownership trends. How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Atomera (ATOM), Taiwan Semiconductor Manufacturing (TSM) and Micron Technology (MU). Company Calendar Last Earnings8/14/2026Today10/27/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 4 days ago, CUE's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CUE CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees29Year Founded2015Price Target and Rating Average Price Target for Cue Biopharma$83.00 High Price Target$83.00 Low Price Target$83.00 Potential Upside/Downside+355.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($27.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.60 million Net Margins-435.83% Pretax Margin-434.50% Return on Equity-620.06% Return on Assets-291.15% Debt Debt-to-Equity RatioN/A Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual Sales$37.66 million Price / Sales3.51 Cash FlowN/A Price / Cash FlowN/A Book Value$10.08 per share Price / Book1.81Miscellaneous Outstanding Shares7,264,000Free Float6,206,000Market Cap$132.23 million OptionableNo Data Beta2.62 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CUE) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredBig Gains on Tap as Sub-US$1 Silver-Gold Discovery Takes ShapeA small-cap North American silver-gold explorer has unified a historic, fragmented mining district under one o...Resource Stock Digest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
